Abstract:As a class of microtubule targeting agents, colchicine binding site inhibitors (CBSIs) are considered as promising drug candidates for cancer therapy. However, due to adverse reactions, there are currently no CBSIs approved by FDA for cancer treatment. Therefore, extensive efforts are still encouraged to find novel CBSIs with different chemical structures and better anticancer efficacies. In this work, we designed and synthesized a new coumarin-dihydroquinoxalone derivative, MY-673, and evaluated its anticancer potency in vitro and in vivo. We confirmed that MY-673 was a potent CBSI that it not only inhibited tubulin polymerization, but also exhibited significant inhibitory potency on the growth of 13 cancer cells with IC<sub>50</sub> values from 11.7 nM to 395.9 nM. Based on the results of kinase panel screening, MY-673 could inhibit ERK (extracellular regulated protein kinases) pathways-related kinases. We further confirmed that MY-673 could inhibit ERK signaling pathway in MGC-803 and HGC-27 cells, and then affected the expression level of SMAD4 protein in TGF-β (transforming growth factor β) /SMAD (small mother against decapentaplegic) signaling pathway using the western blotting assay. In addition, compound MY-673 could effectively inhibit cell proliferation, migration and induce cell apoptosis. We also further confirmed the in vivo efficacy of MY-673 in inhibiting tumor growth using the MGC-803 xenograft tumor model. At 20 mg/kg, the TGI rate was 85.9%, and it did not cause obvious toxicity to the main organs of mice. Together, the results we report here indicated that MY-673 was a promising CBSI for cancer treatment, which was capable of inhibiting the ERK pathway with potent antiproliferative activities in vitro and in vivo.

Discovery of potent natural product higenamine derivatives as novel Anti-Fusobacterium nucleatum agents

Discovery of Natural Berberine-Derived Nitroimidazoles As Potentially Multi-Targeting Agents Against Drug-Resistant Escherichia Coli

Discovery of New Fusobacterium Nucleatum Inhibitors to Attenuate Migratory Capability of Colon Cancer Cells by the Drug Repositioning Strategy.

Novel Aminopyrimidinyl Benzimidazoles As Potentially Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Unique Aminothiazolyl Coumarins As Potential DNA and Membrane Disruptors Towards Enterococcus Faecalis

Vanillin Derivatives Reverse Fusobacterium nucleatum-Induced Proliferation and Migration of Colorectal Cancer Through E-Cadherin/β-Catenin Pathway

Antibacterial activity of N-methylbenzofuro[3,2-b]quinoline and N-methylbenzoindolo[3,2-b]-quinoline derivatives and study of their mode of action

Sodium New Houttuyfonate Inhibits Cancer-Promoting Fusobacterium nucleatum (Fn) to Reduce Colorectal Cancer Progression

The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates

Screening inhibitors against the Ef-Tu of Fusobacterium nucleatum: a docking, ADMET and PBPK assessment study

Discovery of Novel Bacterial FabH Inhibitors (Pyrazol-Benzimidazole Amide Derivatives): Design, Synthesis, Bioassay, Molecular Docking and Crystal Structure Determination

Discovery of Cinnamic Acid Derivatives as Potent Anti-H. pylori Agents

Dencichine attenuates the virulence of Fusobacterium nucleatum by targeting hydrogen sulfide-producing enzyme

Natural Products‐Based Anticancer Agents: Synthesis and Anticancer Activities of Funtumine Amide/sulfonamide Derivatives

Exploration and Biological Evaluation of 1,3-Diamino-7h-pyrrol[3,2-f]quinazoline Derivatives As Dihydrofolate Reductase Inhibitors.

Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides As DNA Gyrase B-targeted Antibacterial Agents

Discovery of a novel Coumarin-Dihydroquinoxalone derivative MY-673 as a tubulin polymerization inhibitor capable of inhibiting the ERK pathway with potent anti-gastric cancer activities

Design, synthesis, and biological evaluation of membrane-active honokiol derivatives as potent antibacterial agents

Antibacterial Fusobacterium Nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐colonized Bacteria And Enhance Immunotherapy Against Colorectal Cancer

Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges